Last reviewed · How we verify
Sickle Cell Disease
Approved treatments
- Oxbryta · Global Blood Theraps
Voxelotor inhibits HbS polymerization by increasing oxygen affinity, potentially reducing RBC sickling and improving deformability.
Pipeline
- Inclacumab · Pfizer Inc. — discontinued
- HYDROXYUREA — Phase 3
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Sickle Cell Disease patent landscape — cliff calendar, originator estates, attackable patents
- Sickle Cell Disease treatment landscape brief
- Sickle Cell Disease treatment updates RSS
Frequently asked questions about Sickle Cell Disease
What drugs treat Sickle Cell Disease?
Tracked treatments include Oxbryta.
What is the treatment for Sickle Cell Disease?
Standard treatment for Sickle Cell Disease includes Oxbryta. See the treatment landscape page for first-line, second-line and salvage options.
What new drugs are in development for Sickle Cell Disease?
2 pipeline drugs tracked. Top candidates: Inclacumab, HYDROXYUREA.
Related
- Treatment landscape: Sickle Cell Disease patent cliff · Sickle Cell Disease CI report
- Treatment: Oxbryta · Global Blood Theraps
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing